Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial

Riccardo Bruna,Fabio Benedetti,Carola Boccomini,Caterina Patti,Anna Maria Barbui,Alessandro Pulsoni,Maurizio Musso,Anna Marina Liberati,Guido Gini,Claudia Castellino,Fausto Rossini,Fabio Ciceri,Delia Rota-Scalabrini,Caterina Stelitano,Francesco di Raimondo,Alessandra Tucci,Liliana Devizzi,Valerio Zoli,Francesco Zallio,Franco Narni,Alessandra Dondi,Guido Parvis,Gianpietro Semenzato,Francesco Lanza,Tommasina Perrone,Francesco Angrilli,Atto Billio,Angela Gueli,Barbara Mantoan,Alessandro Rambaldi,Alessandro Massimo Gianni,Paolo Corradini,Roberto Passera,Marco Ladetto,Corrado Tarella

Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial

2019

A prospective trial conducted in 2000-2005 showed no survival advantage for high-dose chemotherapy with rituximab and autograft (R-HDS) versus conventional chemotherapy with rituximab (CHOP-R) as first-line therapy in 134 high-risk follicular lymphoma patients aged

Keywords:

Oncology
Diabetes mellitus
Immunology
Follicular lymphoma
Disease
Immunotherapy
Medicine
Internal medicine
Rituximab
advanced stage
MEDLINE
chemo immunotherapy
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations